Clinical Trials Sponsored by Carsgen Therapeutics, Ltd.

Total 463 results

CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
CARsgen Therapeutics Co., Ltd.

Unknown

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

China
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Gastric Cancer | Pancreatic Cancer

United States, Canada
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Zhejiang University
CARsgen Therapeutics Co., Ltd.

Completed

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Advanced Hepatocellular Carcinoma

China
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Completed

CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19 Positive Malignant B-cell Leukemia and Lymphoma

China
Zhejiang University
CARsgen Therapeutics Co., Ltd.

Recruiting

Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
CARsgen Therapeutics Co., Ltd.
Shanghai East Hospital

Active, not recruiting

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
First Affiliated Hospital of Zhejiang University
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Caregen Co. Ltd.

Not yet recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug

Healthy
CARsgen Therapeutics Co., Ltd.
Fudan University; Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma | Plasma Cell Leukemia

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

PBMC Collection for Production of UCAR T Cells

Peripheral Blood Mononuclear Cell

China
CuraGen Corporation

Completed

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Stomatitis | Oral Mucositis

United States
CuraGen Corporation

Completed

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
CuraGen Corporation

Completed

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

Stomatitis

United States
CuraGen Corporation

Completed

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
Peking University
CARsgen Pharmaceuticals Co.,Ltd

Recruiting

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Xinhua Hospital, Shanghai Jiao Tong University...
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Kang YU
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Hepatocellular Carcinoma | B Cell Lymphoma | Pancreatic Carcinoma | Myeloma | B Cell Leukemia | Adenocarcinoma of Esophagogastric Junction

China
Caregen Co. Ltd.
CBCC Global Research

Not yet recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration

United States
NeuroSense Therapeutics Ltd.

Recruiting

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. (RoAD)

Alzheimer Disease

Israel
Iksuda Therapeutics Ltd.

Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

Breast Cancer | Gastric Cancer | Gastroesophageal-junction Cancer

Australia
Amber Therapeutics Ltd

Not yet recruiting

AURA 1: Augmenting Urinary Reflex Activity: Study 1 (AURA1)

Overactive Bladder | Urge Incontinence
Enlivex Therapeutics Ltd.

Not yet recruiting

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Covid19
Raziel Therapeutics Ltd.

Completed

RZL-012 for Dercum's Disease Lipomas

Dercum's Disease Lipomas

United States
Raziel Therapeutics Ltd.

Completed

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Flank Mass

United States
Raziel Therapeutics Ltd.

Completed

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Submental Fat

United States
Nerre Therapeutics Ltd.

Completed

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Chronic Refractory Cough

United States, Canada, United Kingdom
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Immodulon Therapeutics Ltd

Completed

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

Spain, United Kingdom, Italy, Cyprus, Ireland
Prescient Therapeutics, Ltd.

Terminated

PTX-200 and Carboplatin in Ovarian Cancer

Ovarian Cancer

United States
Nerre Therapeutics Ltd.

Completed

Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects

Healthy

United Kingdom
Enlivex Therapeutics Ltd.

Completed

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS (P-SOFA-1)

Organ Dysfunction Syndrome Sepsis

Israel
TauRx Therapeutics Ltd

Completed

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Behavioral Variant Frontotemporal Dementia (bvFTD)

United States, Australia, Canada, Croatia, Poland, Netherlands, United Kingdom, Spain, Germany, Italy, Romania, Singapore
PhytoTech Therapeutics, Ltd.

Completed

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Healthy Volunteers

Israel
TauRx Therapeutics Ltd

Terminated

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Alzheimer's Disease

Germany, United Kingdom
Chronos Therapeutics Ltd

Completed

A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Ark Therapeutics Ltd

Terminated

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence (AdV-VANTAGE)

End Stage Renal Disease

United States
TauRx Therapeutics Ltd

Completed

TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

Dementia, Alzheimer Type
CMP Therapeutics Ltd

Completed

Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis

Seasonal Allergic Rhinitis

Clinical Trials Sponsored by Carsgen Therapeutics, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations